Science

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer

Mark M. Awad/mskcc.org

Jan 15, 2025, 15:32

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer

Dipesh Uprety, Assistant Professor of Thoracic Oncology at the Barbara Ann Karmanos Cancer Institute, shared an article by Mark M. Awad on X:

“Phase III CheckMate-816 Journal of Clinical Oncology Neoadjuvant Nivo + Ipi vs Chemo:-

Md EFS 54.8 mo vs 20.4 mo.
pCR 20.4 vs 4.6 MPR 28.3 vs 14.8%.
pCR or MPR had higher baseline 4-gene inflammatory scores than those without in IO arm.”

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.

Authors: Mark M. Awad, et al.

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer

Dipesh Uprety, Assistant Professor of Thoracic Oncology at the Barbara Ann Karmanos Cancer Institute, specializes in treating lung cancer, mesothelioma, thymoma, and thymic carcinoma. He also serves as the Editor-in-Chief of The Cancer News, an authoritative resource on cancer-related topics.

Barbara Ann Karmanos Cancer Institute cancer chemotherapy clinical oncology Dipesh Uprety fight against cancer Global fight against cancer ipilimumab Lung cancer Mark M. Awad neoadjuvant nivolumab OncoDaily Oncology

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage